Search for: "losartan"
Results 41 - 60
of 74
Sorted by Relevance
|
Sort by Date
23 Apr 2009, 10:00 pm
(Spicy IP) India: Assessing India’s innovation climate (Biotech Blog) Kenya’s anti-counterfeit legislation, India protest (Afro-IP) Mexico: Pharmaceutical trade marks: the Health Law pitfall for applicants (International Law Office) US: BIO IP Counsels’ Committee: Q Todd Dickinson and E Anthony Figg on patent reform (Patent Docs) US: Amgen VP makes case for longer exclusivity period in follow-on biologics legislation (Patent Docs) Products Cepham –… [read post]
14 Oct 2009, 7:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Angiomax (Bivalirudin) – US: Medicines Company files patent infringement suit against PLIVA, Barr, Teva following Para IV challenge (Patent Docs) (America-Israel Patent Law) (The IP Factor) (GenericsWeb) Humira (Adalimumab) – US: E D Texas find ‘close issue of claim construction’ supports JMOL of no… [read post]
1 Jul 2009, 7:14 am
(Patent Docs) Products Avapro (Irbesartan) – Spain: Fourth Commercial Court of Barcelona rejects preliminary injunction petition by Sanofi-Aventis and Bristol-Myers Squibb for alleged patent infringement (International Law Office) Cozaar/Hyzaar (Losartan/Hydrochlorothiazide and Losartan) –US: Teva sues FDA over generic Cozaar and Hyzaar 180-day exclusivity forfeiture and patent delisting rule (The FDA Law Blog) Eloxatin (Oxaliplatin) – US: District… [read post]
5 Aug 2009, 5:35 am
(Spicy IP) Coversyl (Perindopril) – Canada: Court of Appeal upholds Trial Division finding of patent validity and infringement: Apotex v ADIR (Pharmacapsules@Gowlings) Cozaar (Losartan) – France: French Patent Office grants paediatric extension of French SPC for Losartan (The SPC Blog) Cozaar/Hyzaar (Losartan) – US: FDA prevails in generic Cozaar/Hyzaar 180-day exclusivity forfeiture litigation: Teva Pharmaceuticals v Sebelius (FDA Law Blog)… [read post]
15 Oct 2010, 12:47 pm
At issue is generic Cozaar® (losartan potassium), Merck's blockbuster angiotensin II receptor antagonist. [read post]
14 Aug 2011, 5:07 am
ARBs (angiotensin receptor blockers) include Valsartan (one tradename Diovan) and Losartan (one tradename Cozaar). [read post]
15 Sep 2011, 10:23 am
Common ACEIs and ARBs ACEIs Lotensin (benazepril) Capoten (captopril) Vasotec (enalapril) Monopril (fosinopril) Prinivil, Zestril (lisinopril) Univasc (moexipril) Aceon (perindopril) Accupril (quinapril) Altace (ramipril) Mavik (trandolapril) ARBs Atacand (candesartan) Teveten (eprosartan) Avapro (irbesartan) Cozaar (losartan) Benicar (olmesartan) Micardis (telmisartan) Diovan (valsartan) Contact an Experienced… [read post]
5 Jan 2022, 7:16 am
The case, In Re Valsartan, Losartan, and Irbesartan Products Liability Litigation (US DC NJ) MDL No. 2875 (RBK)is a products liability case that concerns the sale in the U.S. of generic, prescription Valsartan pharmaceuticals, found by the Food and Drug Administration [“FDA”] to contain cancer‐causing contaminants. [read post]
27 Apr 2011, 4:55 am
(IP Watch) China: Pfizer starts R&D in China after IPR in China challenges (IP Dragon) UK: IPO inviting comment on C-630/10 University of Queensland, CSL Ltd v Comptroller-General of Patents, Designs and Trade Marks and C-130/11 Neurim v Comptroller General of Patents (The SPC Blog) (The SPC Blog) US: New generics quickly grab 80% of sales volume (GenericsWeb) Products Actos (Pioglitazone) – US: Takeda agrees to dismiss one Actos infringement suit against Apotex (Patent Docs) Angiomax… [read post]
27 Dec 2021, 4:00 am
Valsartan and Losartan are two popular drugs that lower blood pressure and were recalled due to NDMA contamination. [read post]
24 Nov 2010, 12:37 am
Use of pipeline system (IP tango) EU: Notes from EU Parliament meeting on innovation+access for medical technologies (KEI) Netherlands: District Court of The Hague declares Dutch part of Bayer’s European patent covering anti-TNF alpha human monoclonal antibodies invalid (Kluwer Patent Blog) Southeast Asia: Generic drug market picks up steam in Southeast Asia, finds Front & Sullivan (GenericsWeb) Spain: Commercial Court No 5 of Barcelona: obtaining price for generic medicament an act of… [read post]
21 Oct 2009, 6:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) – US: Shire announces settlement… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with Sandoz over… [read post]
20 May 2010, 6:30 am
First, some details on the specific actions: (A) A shipment of the generic drug Losartan Potassium, produced in India and destined to Brazil, was seized when in transit at Schipol Airport, in the Netherlands, in December 2008, and later returned to the country of origin. [read post]
18 Mar 2010, 2:30 am
(Patent Docs) Cozaar (Losartan), Hyzaar (Hydrochlorothiazide, Losartan) – US: Court of Appeals for District of Columbia Circuit orders and declares that Teva has not forfeited 180-day exclusivity for Cozaar/Hyzaar (FDA Law Blog) Eloxatin (Oxaliplatin) – US: Sanofi/Sun Deal over generic Eloxatin deemed enforceable (Patent Docs) Ery Tab (Erythromycin) – US: District Court N D Illinois: False marking complaint over marking of Ery Tab product: Simonian v. [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with Sandoz over… [read post]
24 Apr 2019, 9:05 pm
FDA cited Kellogg’s Honey Smacks, recalled vegetables, romaine lettuce, angiotensin II receptor blocker (ARB) drugs like Valsartan, Losartan and Irbesartan, King Bio homeopathic products, test strips for home-use monitoring of Warfarin, and contaminated pet food as recent examples of where strengthen recalls have worked. [read post]
25 Mar 2025, 5:42 am
., Lisinopril, Losartan Dangers of Stopping Suddenly: Rebound hypertension (dangerously high blood pressure) Increased risk of heart attack or stroke Rapid heartbeat, chest pain, and anxiety How to Stop Safely: Gradual dose reduction under a doctor’s guidance is crucial to avoid dangerous spikes in blood pressure. 6. [read post]
6 Jul 2010, 6:03 pm
(Patent Docs) (Holman’s Biotech IP Blog) US: AMP v USPTO after Bilski v Kappos (Patent Docs) US: NORD Chair/HP&M Director presents opening testimony at first ever FDA orphan drug hearing (FDA Law Blog) US: Celsis files patent infringement complaint against CellzDirect and Invitrogen over pooled multi-cryopreserved hepatocyte products (Patent Docs) Products Astelin (Azelastine) – US: Zydus admits infringing Meda’s Astelin patent, agrees not to market generic (Patent Docs)… [read post]
19 May 2010, 6:15 am
(Patent Docs) Products Actos and Actoplus Met (Pioglitazone) - Sandoz and Takeda settle patent dispute over Actos and Actoplus Met (Patent Docs) Cozaar / Hyzaar (Losartan) – US: DC Circuit denies FDA’s petition for panel rehearing and rehearing en banc; Roxane/Apotex case continues (FDA Law Blog) Entocort (Budesonide) – US: Teva reaches settlement agreement with AstraZeneca regarding generic Entocort capsules (SmartBrief) Levaquin (Levafloxicin) - US: CAFC decision… [read post]
